MSK Department of Medicine
@mskdeptofmed.bsky.social
The official account of @mskcancercenter.bsky.social's Department of Medicine. Chair/Dept. Head: Deb Schrag
At #Tandem26, @drmiguelperales.bsky.social, MSK's Adult Bone Marrow Transplant Chief and past @astct.bsky.social President, will present research on new tools to help predict one-year survival for transplant recipients. @mskcancercenter.bsky.social
📍Feb 4, 11:15 a.m. MST
➡️ bit.ly/4tg4Rz1
📍Feb 4, 11:15 a.m. MST
➡️ bit.ly/4tg4Rz1
February 4, 2026 at 5:34 PM
At #Tandem26, @drmiguelperales.bsky.social, MSK's Adult Bone Marrow Transplant Chief and past @astct.bsky.social President, will present research on new tools to help predict one-year survival for transplant recipients. @mskcancercenter.bsky.social
📍Feb 4, 11:15 a.m. MST
➡️ bit.ly/4tg4Rz1
📍Feb 4, 11:15 a.m. MST
➡️ bit.ly/4tg4Rz1
Dr. Sergio Giralt is kicking off #Tandem26 for @mskcancercenter.bsky.social! Join his session to learn about the latest CAR T cell therapies for #multiplemyeloma.
📍 Feb 4, 9:05 a.m.–9:35 a.m. MST | Room 255 A-G
➡️ https://bit.ly/4rgYf25
@astct.bsky.social @cibmtr.bsky.social #mmsm
📍 Feb 4, 9:05 a.m.–9:35 a.m. MST | Room 255 A-G
➡️ https://bit.ly/4rgYf25
@astct.bsky.social @cibmtr.bsky.social #mmsm
February 4, 2026 at 2:45 PM
Dr. Sergio Giralt is kicking off #Tandem26 for @mskcancercenter.bsky.social! Join his session to learn about the latest CAR T cell therapies for #multiplemyeloma.
📍 Feb 4, 9:05 a.m.–9:35 a.m. MST | Room 255 A-G
➡️ https://bit.ly/4rgYf25
@astct.bsky.social @cibmtr.bsky.social #mmsm
📍 Feb 4, 9:05 a.m.–9:35 a.m. MST | Room 255 A-G
➡️ https://bit.ly/4rgYf25
@astct.bsky.social @cibmtr.bsky.social #mmsm
Reposted by MSK Department of Medicine
Researchers at MSK are studying the intricacies of metastatic disease to develop new ways to treat it and improve outcomes for patients with stage 4 #cancer. Learn how MSK is making progress against #metastasis.
Making Progress Against Metastasis
While there has been remarkable progress in the number of people surviving with stage 4 cancer, MSK remains dedicated to research that will spur much needed advances.
www.mskcc.org
January 27, 2026 at 2:27 PM
Researchers at MSK are studying the intricacies of metastatic disease to develop new ways to treat it and improve outcomes for patients with stage 4 #cancer. Learn how MSK is making progress against #metastasis.
Reposted by MSK Department of Medicine
New research from MSK sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of #glioma-associated macrophages that appear to play a pivotal role in progression; and more.
MSK Research Highlights, January 20, 2026
New MSK research sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of glioma-associated macrophages that appear to play a pivotal role in progression; and demonst...
www.mskcc.org
January 26, 2026 at 2:34 PM
New research from MSK sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of #glioma-associated macrophages that appear to play a pivotal role in progression; and more.
Reposted by MSK Department of Medicine
Medical oncologist @drmiguelperales.bsky.social, Chief of the Adult Bone Marrow Transplant Service at MSK, shares 10 reasons why MSK's BMT program continues to be a leader in the field of transplantation. bit.ly/3NnAZQI
January 14, 2026 at 9:23 PM
Medical oncologist @drmiguelperales.bsky.social, Chief of the Adult Bone Marrow Transplant Service at MSK, shares 10 reasons why MSK's BMT program continues to be a leader in the field of transplantation. bit.ly/3NnAZQI
Congrats to Eytan Stein & collaborators on receiving "2025 Paper of the Year” from @jco-asco.bsky.social for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. Study results led to the drug's FDA approval in 2024. @mskcancercenter.bsky.social
➡️ https://bit.ly/3LH5G2R
➡️ https://bit.ly/3LH5G2R
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia
Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer...
www.mskcc.org
January 14, 2026 at 7:28 PM
Congrats to Eytan Stein & collaborators on receiving "2025 Paper of the Year” from @jco-asco.bsky.social for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. Study results led to the drug's FDA approval in 2024. @mskcancercenter.bsky.social
➡️ https://bit.ly/3LH5G2R
➡️ https://bit.ly/3LH5G2R
Reposted by MSK Department of Medicine
Congratulations to Dr. Ross Levine (@rosslevinemd.bsky.social), MSK's Chief Scientific Officer, who was appointment editor-in-chief of Blood Cancer Discovery, published by @theaacr.bsky.social.
Learn more: bit.ly/4qR5Qn1
Learn more: bit.ly/4qR5Qn1
January 13, 2026 at 4:09 PM
Congratulations to Dr. Ross Levine (@rosslevinemd.bsky.social), MSK's Chief Scientific Officer, who was appointment editor-in-chief of Blood Cancer Discovery, published by @theaacr.bsky.social.
Learn more: bit.ly/4qR5Qn1
Learn more: bit.ly/4qR5Qn1
Collaborators Eric Van Cutsem, Yelena Janjigian, & Kohei Shitara caught up at #GI26. Dr. Janjigian shared a trial in progress of a 1st line combination for HER2-low #gastriccancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma. @mskcancercenter.bsky.social.
bit.ly/4aSddGo
bit.ly/4aSddGo
January 8, 2026 at 10:58 PM
Collaborators Eric Van Cutsem, Yelena Janjigian, & Kohei Shitara caught up at #GI26. Dr. Janjigian shared a trial in progress of a 1st line combination for HER2-low #gastriccancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma. @mskcancercenter.bsky.social.
bit.ly/4aSddGo
bit.ly/4aSddGo
Coming up at #GI26, Dr. Geoffrey Ku will give a medical oncologist's perspective on the role of local and systemic treatments in metastatic #gastriccancer and #gastroesophagealcancer @mskcancercenter.bsky.social #GICancers @ascocancer.bsky.social
3:45 – 5 p.m. PST | Level 3, Room 3001
3:45 – 5 p.m. PST | Level 3, Room 3001
January 8, 2026 at 9:26 PM
Coming up at #GI26, Dr. Geoffrey Ku will give a medical oncologist's perspective on the role of local and systemic treatments in metastatic #gastriccancer and #gastroesophagealcancer @mskcancercenter.bsky.social #GICancers @ascocancer.bsky.social
3:45 – 5 p.m. PST | Level 3, Room 3001
3:45 – 5 p.m. PST | Level 3, Room 3001
We're excited for @ascocancer.bsky.social #GI26! Stop by Dr. Steve Maron's poster to learn about a phase 2 trial of amivantamab for EGFR- or MET-amplified #gastroesophageal #adenocarcinoma. @mskcancercenter.bsky.social #GICancer
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
January 8, 2026 at 3:59 PM
We're excited for @ascocancer.bsky.social #GI26! Stop by Dr. Steve Maron's poster to learn about a phase 2 trial of amivantamab for EGFR- or MET-amplified #gastroesophageal #adenocarcinoma. @mskcancercenter.bsky.social #GICancer
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
Research co-led by MSK scientists found a gene variant that may reduce the risk of developing certain #bloodcancers associated with #clonalhematopoiesis. Learn more about how @mskcancercenter.bsky.social is leading the way in CH research and treatment.
Also check out our CH clinic: bit.ly/49szicf
Also check out our CH clinic: bit.ly/49szicf
Scientists have known for decades that there are gene mutations that increase your risk of developing cancer. But there is also a genetic variant that could reduce the risk of developing certain #bloodcancers, according to new research co-led by scientists from MSK.
Learn more: bit.ly/4sIJ5DQ
Learn more: bit.ly/4sIJ5DQ
January 7, 2026 at 7:33 PM
Research co-led by MSK scientists found a gene variant that may reduce the risk of developing certain #bloodcancers associated with #clonalhematopoiesis. Learn more about how @mskcancercenter.bsky.social is leading the way in CH research and treatment.
Also check out our CH clinic: bit.ly/49szicf
Also check out our CH clinic: bit.ly/49szicf
Congrats to Dr. Deb Schrag, the Department of Medicine's fearless leader, on being elected as the 2027–2028 @ascocancer.bsky.social President! She has devoted her career to accelerating progress for people with #cancer, and we can't wait to witness the amazing things she will do next. #oncology
Congratulations to Dr. Deb Schrag, a gastrointestinal medical oncologist and Chair of the Department of Medicine at MSK, on being elected as the 2027-28 President of the @ascocancer.bsky.social.
Read more: bit.ly/3N8Nf7q
Read more: bit.ly/3N8Nf7q
December 19, 2025 at 5:08 PM
Congrats to Dr. Deb Schrag, the Department of Medicine's fearless leader, on being elected as the 2027–2028 @ascocancer.bsky.social President! She has devoted her career to accelerating progress for people with #cancer, and we can't wait to witness the amazing things she will do next. #oncology
Reposted by MSK Department of Medicine
🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK.
Learn more: bit.ly/4iVd9Y6
Learn more: bit.ly/4iVd9Y6
December 15, 2025 at 8:22 PM
🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK.
Learn more: bit.ly/4iVd9Y6
Learn more: bit.ly/4iVd9Y6
Reposted by MSK Department of Medicine
MSK genitourinary oncologist Dr. Rosenberg has led multiple clinical trials testing enfortumab vedotin alone or in combination with others for #bladdercancer. Learn more ⬇️
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients
A powerful therapy called an antibody-drug conjugate has been approved by the FDA for more people with bladder cancer.
www.mskcc.org
December 16, 2025 at 7:10 PM
MSK genitourinary oncologist Dr. Rosenberg has led multiple clinical trials testing enfortumab vedotin alone or in combination with others for #bladdercancer. Learn more ⬇️
Don't miss Dr. Zsofia Stadler's presentation "Identification of inherited #cancer syndromes: Re-defining early-onset cancers" at #AACRearlyonset25. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social @theaacr.bsky.social
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
December 13, 2025 at 2:00 PM
Don't miss Dr. Zsofia Stadler's presentation "Identification of inherited #cancer syndromes: Re-defining early-onset cancers" at #AACRearlyonset25. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social @theaacr.bsky.social
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
At the @theaacr.bsky.social special conference on the rise of early-onset #cancers, Dr. Luis Diaz will present in a session about opportunities for early interception. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
December 13, 2025 at 1:00 PM
At the @theaacr.bsky.social special conference on the rise of early-onset #cancers, Dr. Luis Diaz will present in a session about opportunities for early interception. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
Reposted by MSK Department of Medicine
Dr. Jun Mao, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @sabcs.bsky.social .
Learn more: bit.ly/4aeZAkg
Learn more: bit.ly/4aeZAkg
December 12, 2025 at 6:09 PM
Dr. Jun Mao, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @sabcs.bsky.social .
Learn more: bit.ly/4aeZAkg
Learn more: bit.ly/4aeZAkg
Reposted by MSK Department of Medicine
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML | OncLive
TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.
www.onclive.com
December 12, 2025 at 5:19 PM
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...
Reposted by MSK Department of Medicine
Results from #SABCS25: A trial, reported by breast cancer medical oncologist @breastcancerdoc.bsky.social, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy.
bit.ly/3MGgZs6
bit.ly/3MGgZs6
December 12, 2025 at 7:38 PM
Results from #SABCS25: A trial, reported by breast cancer medical oncologist @breastcancerdoc.bsky.social, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy.
bit.ly/3MGgZs6
bit.ly/3MGgZs6
Reposted by MSK Department of Medicine
HAPPENING SOON at #SABCS25: MSK breast surgeon Dr. Giacomo Montagna will present research on the de-escalation of axillary surgery after NAC in clinically node positive patients.
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
December 11, 2025 at 6:06 PM
HAPPENING SOON at #SABCS25: MSK breast surgeon Dr. Giacomo Montagna will present research on the de-escalation of axillary surgery after NAC in clinically node positive patients.
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
Reposted by MSK Department of Medicine
TODAY at the #SABCS25: Dr. Jun Mao, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @sabcs.bsky.social
🗓️: December 12 at 9 a.m. (CST)
🗓️: December 12 at 9 a.m. (CST)
December 12, 2025 at 2:41 PM
TODAY at the #SABCS25: Dr. Jun Mao, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @sabcs.bsky.social
🗓️: December 12 at 9 a.m. (CST)
🗓️: December 12 at 9 a.m. (CST)
We're excited for AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers! @karunamdphd.bsky.social will discuss the role of pks⁺ E. coli in early-onset #colorectalcancer. @theaacr.bsky.social @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
December 12, 2025 at 5:05 PM
We're excited for AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers! @karunamdphd.bsky.social will discuss the role of pks⁺ E. coli in early-onset #colorectalcancer. @theaacr.bsky.social @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
#SABCS25 posters! Visit Dr. Tiffany Traina to learn about the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
December 12, 2025 at 3:02 PM
#SABCS25 posters! Visit Dr. Tiffany Traina to learn about the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
Coming up at #SABCS25: @breastcancerdoc.bsky.social will present updated results from the phase 3 EMBER-3 trial of imlunestrant with or without abemaciclib for advanced #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
December 12, 2025 at 1:01 PM
Coming up at #SABCS25: @breastcancerdoc.bsky.social will present updated results from the phase 3 EMBER-3 trial of imlunestrant with or without abemaciclib for advanced #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
Join @sherryshenmd.bsky.social for a presentation on adjuvant therapy decisions in HR+HER2- #breastcancer in the era of axillary de-escalation. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social #SABCS25
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
December 11, 2025 at 4:02 PM
Join @sherryshenmd.bsky.social for a presentation on adjuvant therapy decisions in HR+HER2- #breastcancer in the era of axillary de-escalation. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social #SABCS25
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8